The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation.
Susanna S NgFabian De Labastida RiveraJuming YanDillon CorvinoIndrajit DasPing ZhangRachel KunsShashi Bhushan ChauhanJiajie HouXian-Yang LiTeija C M FrameBenjamin A McEnroeEilish MooreJinrui NaJessica A EngelMegan S F SoonBhawana SinghAndrew J KuehMarco J HeroldMarcela Montes de OcaSiddharth Sankar SinghPatrick T BunnAmy Roman AguileraMika CaseyMatthias BraunNazanin GhazanfariShivangi WaniYulin WangFiona H AmanteChelsea L EdwardsAshraful HaqueWilliam C DougallOm Prakash SinghAlan G BaxterMichele W L TengAlex LoukasNorelle L DalyNicole CloonanMariapia A Degli-EspostiJude UzonnaWilliam R HeathTobias BaldSiok-Keen TeyKyohei NakamuraGeoffrey R HillRajiv KumarShyam SundarMark J SmythChristian R EngwerdaPublished in: Nature immunology (2020)
Immune-modulating therapies have revolutionized the treatment of chronic diseases, particularly cancer. However, their success is restricted and there is a need to identify new therapeutic targets. Here, we show that natural killer cell granule protein 7 (NKG7) is a regulator of lymphocyte granule exocytosis and downstream inflammation in a broad range of diseases. NKG7 expressed by CD4+ and CD8+ T cells played key roles in promoting inflammation during visceral leishmaniasis and malaria-two important parasitic diseases. Additionally, NKG7 expressed by natural killer cells was critical for controlling cancer initiation, growth and metastasis. NKG7 function in natural killer and CD8+ T cells was linked with their ability to regulate the translocation of CD107a to the cell surface and kill cellular targets, while NKG7 also had a major impact on CD4+ T cell activation following infection. Thus, we report a novel therapeutic target expressed on a range of immune cells with functions in different immune responses.